Inverna Therapeutics is a next-generation RNA therapeutics company based in Denmark. The Company was co-founded in 2024 by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting with a lead program addressing Huntington’s disease. The company's drug discovery platform is focused on so-called pseudo-exons, which is a promising class of novel RNA targets.